dupilumab
sanofi,regeneron
['sclc', 'dupilumab', 'nsclc']
. presented today at : a phase 1b/2 trial of dupilumab given in conjunction with pd-(l)1 blockade in the treatment of relapsed/refractory metastatic nsclc. 
Official account of The Tisch Cancer Institute @MountSinaiNYC. Committed to cancer prevention, detection, treatment & research. Appointments:  1-844-MD CANCER